TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective
Masanori Oshi, Makoto Sugimori, Kei Kawashima, Shipra Gandhi, Akimitsu Yamada, Kazutaka Narui, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe · 2026
Read TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective by Masanori Oshi, Makoto Sugimori, Kei Kawashima, Shipra Gandhi, Akimitsu Yamada, Kazutaka Narui, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13371642.txt.
Description
Masanori Oshi and colleagues test whether TP53 mutations change how long breast cancer treatments last in a 2026 study. The focus is hormone-receptor-positive, HER2-negative breast cancer, using real-world data from Japan's C-CAT cohort alongside the METABRIC cohort for survival analysis. Treatment duration served as a real-world proxy for benefit.
TP53-mutated tumours carried a poorer prognosis in METABRIC. In the real-world cohort, TP53 mutation was linked to shorter time on CDK4/6 inhibitors, but not clearly to shorter time on immune checkpoint inhibitors. Age groups from young adults to older patients were compared. The split suggests that TP53 status may help predict which drug class will hold longer for a given patient.
Catalog record
| CREATOR | Masanori Oshi, Makoto Sugimori, Kei Kawashima, Shipra Gandhi, Akimitsu Yamada, Kazutaka Narui, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |